Table 1 Clinical characteristics of patients with Crohn’s disease (N = 168)
From: Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease
Characteristics | Early immuno-modulator therapy | Conventional therapy | P-value | |
|---|---|---|---|---|
Age, yr, median (IQR) | 26.5 (11.0) | 30 (12.3) | 0.137 | |
Sex, (%) | 0.305 | |||
Male | 81 (79.4) | 57 (86.4) | ||
Female | 21 (20.6) | 9 (13.6) | ||
Activity status at start medication, (%) | 0.474 | |||
Remission | 7 (6.9) | 5 (7.6) | ||
Mild | 24 (23.5) | 17 (25.8) | ||
Moderate | 70 (68.6) | 41 (62.1) | ||
Severe | 1 (1.0) | 3 (4.5) | ||
Location, (%) | 0.191 | |||
L1 (ileal) | 9 (8.8) | 2 (3.0) | ||
L2 (colonic) | 13 (12.7) | 7 (10.6) | ||
L3 (ileocolonic) | 16 (15.7) | 13 (19.7) | ||
L4 (only upper GI) | 0 (0) | 3 (4.5) | ||
NA | 64 (62.8) | 41 (62.2) | ||
Behavior at diagnosis, (%) | 0.651 | |||
B1 (non-stricturing, non-penetrating) | 20 (19.6) | 14 (21.2) | ||
B2 (stricturing) | 10 (9.8) | 3 (4.6) | ||
Perianal disease | 8 (7.8) | 8 (12.1) | ||
NA | 64 (62.8) | 41 (62.1) | ||
Initial medication, (%) | <0.001 | |||
Only 5-ASA | 54 (52.9) | 56 (84.8) | ||
5-ASA with steroids | 9 (8.8) | 10 (15.2) | ||
Only immunomodulators | 3 (2.9) | 0 (0) | ||
Immunomodulators with 5-ASA | 36 (35.3) | 0 (0) | ||
CDAI, median (IQR) | 263.0 (119.5) | 249.2 (117.9) | 0.643 | |
BMI, median (IQR) | 19.8 (4.7) | 18.9 (3.7) | 0.141 | |
CRP, median (IQR) | 8.1 (39.2) | 8.9 (24.8) | 0.052 | |
ESR, median (IQR) | 54.0 (59.0) | 55.0 (52.0) | 0.462 | |
Hct, median (IQR) | 38.4 (8.6) | 37.3 (7.2) | 0.905 | |